发布求助
文献互助 智能选刊 最新文献

Urologie最新文献

筛选
英文 中文
[Treatment of BK virus infection in kidney transplant patients].
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-23 DOI: 10.1007/s00120-024-02491-4
Laila Schneidewind
{"title":"[Treatment of BK virus infection in kidney transplant patients].","authors":"Laila Schneidewind","doi":"10.1007/s00120-024-02491-4","DOIUrl":"https://doi.org/10.1007/s00120-024-02491-4","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hepatic hematoma and hemoperitoneum following extracorporeal shock wave lithotripsy (ESWL)]. [体外冲击波碎石术（ESWL）后的肝血肿和腹腔积血]。
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-18 DOI: 10.1007/s00120-024-02492-3
Georg Prange, Badar Uddin, Steffen Relecker, Gesa Dierke
{"title":"[Hepatic hematoma and hemoperitoneum following extracorporeal shock wave lithotripsy (ESWL)].","authors":"Georg Prange, Badar Uddin, Steffen Relecker, Gesa Dierke","doi":"10.1007/s00120-024-02492-3","DOIUrl":"https://doi.org/10.1007/s00120-024-02492-3","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[German Society of Urology fellowships: career booster and opportunity]. [德国泌尿外科学会研究金：职业生涯的助推器和机遇]。
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 Epub Date: 2024-11-11 DOI: 10.1007/s00120-024-02476-3
Christoph Becker, Christian Thomas
{"title":"[German Society of Urology fellowships: career booster and opportunity].","authors":"Christoph Becker, Christian Thomas","doi":"10.1007/s00120-024-02476-3","DOIUrl":"10.1007/s00120-024-02476-3","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1271-1275"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors]. [肾细胞癌辅助治疗：相关患者和肿瘤因素]。
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 Epub Date: 2024-11-15 DOI: 10.1007/s00120-024-02474-5
Jens Bedke, Viktor Grünwald
{"title":"[Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors].","authors":"Jens Bedke, Viktor Grünwald","doi":"10.1007/s00120-024-02474-5","DOIUrl":"10.1007/s00120-024-02474-5","url":null,"abstract":"<p><p>The gold standard in the treatment of localized and locally advanced renal cell carcinoma is surgery. Nevertheless, there is still a risk of tumor relapse. Reducing the risk of recurrence and extending overall survival is the goal of subsequent adjuvant treatment. The aim of this work is to discuss the current and future landscape of adjuvant therapy, taking into account the risk-benefit balance in the individual patient selected for adjuvant treatment. The immune checkpoint inhibitor (CPI) pembrolizumab demonstrated a significant increase in disease-free and overall survival after surgery for the first time. However, other CPI studies demonstrated no improvement. Patient selection for adjuvant treatment is currently based on the parameters of the TNM system. Prospective biomarkers are currently not available. Here, kidney injury molecule‑1 (KIM-1) represents an initial promising biomarker in the prediction of adjuvant immunotherapy.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1224-1231"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Update from d-uo: what can healthcare research contribute to renal cell carcinoma?] [来自 d-uo 的最新消息：医疗保健研究可为肾细胞癌做出哪些贡献？］
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 Epub Date: 2024-11-12 DOI: 10.1007/s00120-024-02465-6
Manfred Johannsen, Rolf Eichenauer, Jörg Klier, Frank König, Robert Schönfelder, Jörg Schröder, Elke Hempel, Christian Doehn
{"title":"[Update from d-uo: what can healthcare research contribute to renal cell carcinoma?]","authors":"Manfred Johannsen, Rolf Eichenauer, Jörg Klier, Frank König, Robert Schönfelder, Jörg Schröder, Elke Hempel, Christian Doehn","doi":"10.1007/s00120-024-02465-6","DOIUrl":"10.1007/s00120-024-02465-6","url":null,"abstract":"<p><strong>Background: </strong>Renal cell carcinoma (RCC) accounts for about 13.5% of all urological tumors. Healthcare research analyzes whether treatment recommendations from controlled studies or guidelines are being implemented in routine care. A prerequisite for the assessment and scientific study of the quality of care in the treatment of urological tumors is standardized documentation.</p><p><strong>Objectives: </strong>This article illustrates healthcare research in RCC by presenting current data from the prospective of the VERSUS study (VERSorgUngsStudie) by d‑uo (Deutsche Uro-Onkologen).</p><p><strong>Materials and methods: </strong>The VERSUS study is a noninterventional, prospective, multicentric study for the documentation and descriptive statistical analysis of the diagnosis, treatment, and aftercare of uro-oncological patients.</p><p><strong>Results: </strong>Of 25,065 patients currently included in the VERSUS study, 1976 have a diagnosis of RCC. Data regarding stage distribution, reason leading to initial diagnosis, distribution of symptomatic vs. asymptomatic patients as well as surgical margins from surgical treatment of RCC are presented.</p><p><strong>Conclusions: </strong>Despite providing interesting results, the VERSUS study remains limited with regard to the depth of the data, since it relies on the same dataset as the German cancer registry. In order to provide more comprehensive healthcare research, organ-related cancer registries like the Urothelial Cancer National Registry (UroNAT) and the Prostate Cancer National Registry (ProNAT) by d‑uo are necessary. These national cancer registries by d‑uo are unique in that they comprise all tumor stages. The Renal Cancer National Registry (ReNAT) by d‑uo is in preparation and will be a valuable contribution to quality assurance of oncological care in Germany.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1246-1250"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Living an error culture]. [错误文化生活］
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 Epub Date: 2024-07-08 DOI: 10.1007/s00120-024-02374-8
Ute Brockhaus
{"title":"[Living an error culture].","authors":"Ute Brockhaus","doi":"10.1007/s00120-024-02374-8","DOIUrl":"10.1007/s00120-024-02374-8","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1281-1284"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Berufspolitik BvDU.
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 DOI: 10.1007/s00120-024-02482-5
{"title":"Berufspolitik BvDU.","authors":"","doi":"10.1007/s00120-024-02482-5","DOIUrl":"https://doi.org/10.1007/s00120-024-02482-5","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 12","pages":"1301-1313"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Contemporary treatment standards and trends of systemic therapy in metastatic hormone-sensitive prostate cancer-implementing study data in clinical practice]. [转移性激素敏感前列腺癌系统治疗的当代治疗标准和趋势--将研究数据应用于临床实践]。
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 Epub Date: 2024-08-14 DOI: 10.1007/s00120-024-02410-7
Mike Wenzel, Séverine Banek, Felix K H Chun, Philipp Mandel
{"title":"[Contemporary treatment standards and trends of systemic therapy in metastatic hormone-sensitive prostate cancer-implementing study data in clinical practice].","authors":"Mike Wenzel, Séverine Banek, Felix K H Chun, Philipp Mandel","doi":"10.1007/s00120-024-02410-7","DOIUrl":"10.1007/s00120-024-02410-7","url":null,"abstract":"<p><strong>Background: </strong>The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has undergone fundamental changes in recent decades, moving away from the sole use of androgen deprivation therapy (ADT) and towards intensified combination therapies.</p><p><strong>Purpose: </strong>To what extent have the data from prospective phase III studies influenced clinical practice in the management of mHSPC over the past 5 or 10 years?</p><p><strong>Results: </strong>A total of 1098 mHSPC patients with a median age at metastasis of 70 years and a median prostate-specific antigen (PSA) level of 43 ng/ml were included in the present study. Significant differences were observed in terms of PSA nadirs in mHSPC after stratification by year of metastatic onset. Significant differences were also observed regarding systemic therapies applied in mHSPC and metastatic castration-resistant prostate cancer (mCRPC; p < 0.001). Regarding the annual estimated percentage change (EAPC) over the past 10 years, a significant decrease in ADT monotherapy from 85% (2013) to 29% (2023; EAPC: -12%, p < 0.001) was observed. Conversely, there was a significant increase in androgen receptor signaling inhibitor (ARSI) use from 6% in 2013 to 55% in 2023 (EAPC: +21.7%, p < 0.001). Regarding docetaxel chemotherapy, a bell-shaped pattern was apparent over the past 10 years, with rates increasing from 8% in 2013 to 25% in 2019 and decreasing to 0% in 2023. The proportion of triplet therapies was 16% in 2023.</p><p><strong>Conclusion: </strong>Over the past 10 years there has been an adaptation of intensified combination therapies for mHSPC in clinical reality, with the most frequent use of ARSI and triplet therapies.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1259-1265"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sind Sie bereit ?
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 DOI: 10.1007/s00120-024-02480-7
{"title":"Sind Sie bereit ?","authors":"","doi":"10.1007/s00120-024-02480-7","DOIUrl":"https://doi.org/10.1007/s00120-024-02480-7","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 12","pages":"1294"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Non-clear cell renal cell carcinoma]. [非透明细胞肾细胞癌]。
IF 0.5 4区 医学
Urologie Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1007/s00120-024-02473-6
Marit Ahrens, Lothar Bergmann
{"title":"[Non-clear cell renal cell carcinoma].","authors":"Marit Ahrens, Lothar Bergmann","doi":"10.1007/s00120-024-02473-6","DOIUrl":"10.1007/s00120-024-02473-6","url":null,"abstract":"<p><p>Non-clear cell renal cell carcinomas (nccRCC) account for approximately 20-25% of renal cell carcinomas. Approximately 20 different histologically and/or molecularly defined entities are subsumed under nccRCC. Many entities only have a share of 1% or less. Due to the rarity of the subpopulations, there are currently no larger randomized studies and there is a some uncertainty regarding the optimal treatment recommendations. The previous treatment recommendations for localized and advanced nccRCC are presented. Data from the various systemic therapies are presented. For nccRCC, there are no different entity-related therapy guidelines due to a lack of data and especially randomized studies. The tumors should be treated in the same way as clear cell renal cell carcinomas. Monotherapies with a tyrosine kinase inhibitor (TKI; in chromophobe RCC also with an mTOR inhibitor) or with combination therapy ICI/ICI or TKI/ICI (ICI: immune checkpoint inhibitor) can be used, depending on the risk factors and individual decision. Randomized trials are urgently needed.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1240-1245"},"PeriodicalIF":0.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信